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Summary
The murine Pten prostate cancer model described in this study recapitulates the disease progression seen in humans:
initiation of prostate cancer with prostatic intraepithelial neoplasia (PIN), followed by progression to invasive adenocarci-
noma, and subsequent metastasis with defined kinetics. Furthermore, while Pten null prostate cancers regress after
androgen ablation, they are capable of proliferating in the absence of androgen. Global assessment of molecular changes
caused by homozygous Pten deletion identified key genes known to be relevant to human prostate cancer, including those
“signature” genes associated with human cancer metastasis. This murine prostate cancer model provides a unique tool
for both exploring the molecular mechanism underlying prostate cancer and for development of new targeted therapies.
Introduction al., 1999). PTEN alteration is strongly implicated in prostate
cancer development. PTEN deletions and/or mutations are
Prostate cancer is the most common malignancy in men and found in 30% of primary prostate cancers (Dahia, 2000; Sellers
the second leading cause of male cancer-related deaths in the and Sawyers, 2002) and 63% of metastatic prostate tissue sam-
Western world. Its development proceeds through a series of ples (Suzuki et al., 1998b), placing PTEN mutation among the
defined states, including prostatic intraepithelial neoplasia (PIN), most common genetic alterations reported in human prostate
prostate cancer in situ, invasive and metastatic cancer. The cancers.
PTEN-controlled signaling pathways are frequently alteredstandard therapies include androgen ablation that initially
causes tumor regression. However, tumor cells will eventually in human prostate cancers, making them promising targets for
therapeutic strategies (DeMarzo et al., 2003; Sellers and Saw-relapse and develop into hormone refractory prostate cancer
(HRPC) (Denis and Murphy, 1993; Landis et al., 1999). yers, 2002; Vivanco and Sawyers, 2002). The major function of
the tumor suppressor PTEN relies on its phosphatase activityThe PTEN (phosphatase and tensin homolog deleted on
chromosome 10) tumor suppressor gene is one of the most and subsequent antagonism of the PI3K/AKT pathway (Cantley
and Neel, 1999; Di Cristofano and Pandolfi, 2000; Maehama etfrequently mutated/deleted genes in various human cancers
(Bose et al., 2002; Deocampo et al., 2003; Sun et al., 2002; al., 2001). Loss of PTEN function, either in murine embryonic
stem cells or in human cancer cell lines, results in accumulationWang et al., 2003; Zhou et al., 2002). Germline mutations in the
PTEN gene have been associated with Cowden syndrome and of PIP3 and activation of its downstream effectors, such as
AKT/PKB (Stambolic et al., 1998; Sun et al., 1999; Wu et al.,related diseases in which patients develop hyperplastic lesions
(harmatomas) in multiple organs with increased risks of malig- 1998). As a serine/threonine protein kinase, AKT functions by
phosphorylating key intermediate signaling molecules, such asnant transformation (Dahia, 2000; Liaw et al., 1997; Marsh et
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Cancer of the prostate is the most common malignancy in men. Study of the biology of prostate cancer and the development of
new therapies have been hampered by a lack of appropriate animal models designed to mimic genetic alterations that are frequently
found in human prostate cancer. The Pten conditional knockout mice characterized in this study fulfilled this demand. Since the
initiating oncogenic event is androgen independent, the Pten conditional deletion mice may provide a unique opportunity to address
the mechanisms of resistance to androgen ablation therapy. By identifying possible downstream targets of PTEN-controlled prostate
tumorigenesis, our findings suggest that studying genetically defined mouse models can yield valuable molecular insights that
impact on human cancer research.
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glycogen synthase kinase-3 (GSK3), BAD, Caspase 9, and IB, Results
leading to increased cell metabolism, cell growth, and cell sur-
Cre-mediated Pten homozygous deletionvival (Di Cristofano and Pandolfi, 2000; Hanahan and Weinberg,
and upregulated AKT activity2000; Vivanco and Sawyers, 2002). Recent studies also suggest
To achieve Pten prostate-specific deletion, we crossed Ptenloxp/loxpthat PTEN may function through AKT-independent mechanisms
mice (Lesche et al., 2002) to the ARR2Probasin-Cre transgenic(Freeman et al., 2003; Gao et al., 2000; Weng et al., 2001).
line, PB-Cre4, in which the Cre recombinase is under the controlInactivation of Pten in mouse models has confirmed PTEN
of a modified rat prostate-specific probasin (PB) promoter (Wuas a bona fide tumor suppressor. Pten/ mice showed a broad
et al., 2001). By crossing PB-Cre4 to a conditional reporterspectrum of spontaneous tumor development, with a bias to-
mouse R26R, the original report indicated that Cre expressionward organs such as large and small intestines, lymphoid, mam-
is specific for prostatic epithelial cells. However, its expressionmary, thyroid, endometrial, and adrenal glands (Di Cristofano
levels vary from lobe to lobe: highest in the lateral lobe (LP),et al., 1998; Podsypanina et al., 1999; Stambolic et al., 2000;
followed by the ventral (VP), dorsal (DP), and least in anteriorSuzuki et al., 1998a). Since homozygous deletion of Pten causes
lobes (AP) (Wu et al., 2001). Since Cre-mediated recombinationearly embryonic lethality, previous studies for prostate cancers
event is a unidirectional process, cells with Cre-mediated genecaused by Pten deletion were invariably using Pten heterozy-
deletion are likely to increase and accumulate over time. Indeed,gous mice. Different rates of prostatic hyperplasia and cancer
a recent follow up study indicated that Cre-mediated recombi-have also been reported in the above studies. Our recent study
nation events increased to near 100% in LP/VP/DP at the agedemonstrated that Pten/ male mice on a Balb/c/129 genetic
of 8 months (Powell et al., 2003).background develop lesions (PIN) with near 100% penetrance
To confirm prostate-specific Pten deletion, the urogenital(D. Freeman et al., submitted). However, the latency for PIN
organs as well as other tissues from Ptenloxp/;Cre mice at theformation is rather long, approximately 10 months, and these
age of 9 and 25 weeks were carefully dissected, and the statusPIN lesions never progress to metastatic disease. These results
of Pten deletion was examined by sensitive PCR and immuno-raised several questions: (1) Does the rate of Pten LOH deter-
histochemistry (IHC) analyses. PCR analysis of 9-week-oldmine the onset of prostate cancer initiation? (2) Is Pten LOH
Ptenloxp/;PB-Cre4 mice showed that Pten deletion, as indi-required for prostate tumor progression? and (3) What genetic
cated by excision of the exon 5 of Pten gene (Pten5), is specificchanges, in addition to Pten deletion, are necessary for prostate
to the prostate gland. Except trace amount of Pten exon 5cancer progression and metastasis?
deletion in the seminal vesicle, all the other tissues testedMice with combined deletion of Pten and other tumor sup-
showed no detectable recombination activity (Figure 1A), con-pressor genes, as possible “second hits,” have been generated.
sistent with the previous report (Wu et al., 2001). Double immu-Pten/;p27/ mice develop prostate carcinoma within 3
nofluorescent analysis demonstrated that PTEN is highly ex-months postnatally with complete penetrance (Di Cristofano et
pressed in cytoplasm and less so in the nucleus of prostatical., 2001). Pten/;Nkx3.1/ compound mutant mice display an
epithelial cells lining the prostatic acini as well as the stromalincreased incidence of high-grade PIN but not prostate cancer
cells surrounding the acini (Figure 1B, left panel; PTEN in red).(Kim et al., 2002). Similarly, Ink4a/Arf deficiency reduced tumor-
Deletion efficiencies of the Pten floxed alleles in different lobesfree survival and shortened the latency of PIN associated with
were similar to the Cre expression pattern reported previously:Pten heterozygosity (You et al., 2002). However, no metastatic
PTEN immunostaining is significantly reduced in the lateral andprostate cancers were reported in these models (Di Cristofano
ventral lobes but only lost or diminished in a subset of the cellset al., 2001; Kim et al., 2002; You et al., 2002). Pten heterozygous
in the dorsal and anterior lobes of 4-week-old Ptenloxp/loxp;PB-mice were also crossed with the well-characterized TRAMP
Cre4 mice (Supplemental Figure S1 at http://www.cancercell.model (Greenberg et al., 1995). Pten LOH significantly shortened
org/cgi/content/full/4/3/209/DC1, LP from WT and mutant micethe average life span of TRAMP mice from 245 days to 159 days
are shown here). By 9 weeks, a majority of the cells in the(Kwabi-Addo et al., 2001). More recently, the MPAKT model was
epithelial compartment of DLP and VP show loss of PTEN immu-created that expressed constitutively activated AKT in mouse
nostaining, and approximately 40%–60% cells in the AP areprostate epithelial cells (Majumder et al., 2003). The MPAKT
PTEN null (Figure 1B, right panels; PTEN in red). Furthermore,mice develop PIN lesions in the ventral prostate with prominent
PTEN immunostaining in the stromal compartment remains pos-bladder obstruction. No progression to metastatic prostate can-
itive, further confirming Pten epithelial-specific deletion.cer was reported (Majumder et al., 2003).
As a result of PTEN loss, the AKT serine/threonine kinase,To assess whether Pten homozygous deletion is critical for
one of the primary targets of the PTEN-controlled signalingprostate cancer progression, we generated Ptenloxp/loxp;PB-Cre4
pathway, is activated. Thus, AKT phosphorylation and plasmamice to achieve prostate-specific Pten deletion. Our studies
membrane localization can serve as reliable indicators for PTENdemonstrated that Pten LOH leads to a significant shortened
loss. AKT phosphorylation is rarely detectable in the WT prostatelatency of PIN formation and results in prostate cancer progres-
(Figure 1B, left panels; P-AKT in green; also see Supplementalsion to a metastatic stage, mimicking the disease progression
Figure S1B on Cancer Cell website) but is highly expressed inseen in humans. The Pten conditional prostate deletion mice
Pten null cells, especially at the plasma membrane of the DLPalso provide a unique opportunity to address the mechanism of
and VP (Figure 1B, right panels; also see Supplemental Figureresistance to androgen ablation therapy in a genetically defined
S1F). Pten null, AKT-activated cells were also larger than theirmodel where the initiating oncogenic event is not androgen
dependent. Our characterization of the Pten model by expres- WT or heterozygous control cells (Supplemental Figure S1, in-
serts), consistent with the role of PTEN in controlling cell sizesion profiling has further indicated that the Pten model has many
additional similarities to human prostate cancers. (Backman et al., 2002; Groszer et al., 2001).
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cific deletion from 4 to 29 weeks. To avoid potential variations
contributed by genetic background, only mice from the F2 gen-
eration were used for studies described below.
Deletion of both alleles of Pten led to progressively enlarged
prostate glands. Histological analysis indicated that from 4
weeks on, the prostates of the mutant mice developed multifocal
hyperplasia. These were initially observed in the dorsolateral
and ventral lobes and subsequently involved the anterior lobes
as well, consistent with the efficiency of Cre-mediated Pten
deletion. Figure 2A shows a comparison of dorsolateral lobes
from WT and their Pten null littermates from 4 to 12 weeks.
Epithelial hyperplasia, characterized by increased number of
cells (without cellular atypia), is seen by 4 weeks of age (Figure
2A, a compared to b). By 6 weeks of age, these mice develop
murine PIN (mPIN). mPIN is the proliferation of atypical epithelial
cells within pre-existing prostatic ductules and acini (Figure 2Ad
and supplemental Figure S2A on Cancer Cell website). This
proliferation results in stratification of the epithelial layer, giving
rise to distinctive architectural features, to include cribiform,
tufting, or micropapillary growth patterns (Figure 2Ad). Cytologi-
cal atypia is characterized by nuclear enlargement, nuclear con-
tour irregularity, hyperchromatism, and prominent nucleoli ac-
companied by the inversion of the nuclear to cytoplasmic ratio
(Figure 2Ac compared to 2Ad; arrows point to atypical cells).
One hundred percent of the homozygous mice developed mPIN
at 6 weeks (Table 1). Thus, homozygous Pten deletion signifi-
cantly shortened the latency for mPIN formation from 8–10
months in heterozygous to 1.5 months in homozygous condi-
tional knockouts. Significantly, Pten null mPIN lesions progress
to invasive and metastatic cancers (see below). These results
demonstrate that (1) homozygous PTEN loss alone is sufficient
for prostate cancer initiation; and (2) Pten LOH is a rate-limiting
step for prostate cancer initiation and progression.
Homozygous Pten deletion leads to invasive adenocarcinoma
While mice with heterozygous Pten deletion develop mPIN late
in their lives (12–16 months, D. Freeman et al., submitted), miceFigure 1. Conditional deletion of Pten tumor suppressor gene in the prostate
with homozygous Pten deletion develop invasive adenocarci-epithelium
noma by 9 weeks of age. Adenocarcinoma was seen in allA: Prostate-specific Pten deletion. Genomic DNAs were prepared from indi-
lobes. Figure 2A compares dorsolateral lobes of WT and mutantvidual prostate lobe and indicated tissues of a 9-week-old Ptenloxp/;PB-
Cre4 male mouse. PCR analysis shows Pten deletion (5) is very prostate prostate at 9 and 12 weeks. From 9 weeks onward, we have
specific: except some leakage in the seminal vesicle, no Pten deletion can observed the extension of malignant cells, either as individual
be detected in tissues other than the prostate. cells or as nests of acini. Initially extending through the base-B: Pten deletion correlates with AKT activation. Double immunofluorescent
ment membrane (Supplemental Figure S2, right panel) and sub-analysis shows the efficiencies of Pten deletion varies from lobe to lobe at
sequently through the fibromuscular layer, as shown by the9 weeks postnatally. PTEN immunostaining (in red) can be detected in both
nuclear and cytoplasmic compartments in the WT prostate (WT, left panels) loss of SMA immunostaining (Supplemental Figure S2, middle
but is almost completely lost (DLP and VP) or diminished (AP) in the Pten panel), the cancer cells then invaded the stroma (Figure 2Af).
conditional mutant (Mut, right panels). In contrast, phosphor-AKT (P-AKT, in
This in turn induces both an inflammatory and a desmoplasticgreen) can be easily detected in Pten null but not Pten WT cells. Note
response (Supplemental Figure S2, right panel). This des-most of stroma cells in the mutant prostate remain PTEN positive, further
confirming prostate epithelium-specific deletion. AP, anterior prostate; DLP, moplastic response is characterized by focal stromal cellularity,
dorsolateral prostate; VP, ventral prostate. found in association with the invasive cancer. These prostate
cancer cells show increased proliferation compared to the WT
controls, as indicated by their Ki67-positive staining (Figure 2B,
left panels).
Prostate epithelium includes basal cells, luminal cells, andPten homozygous deletion shortens latency
neuroendocrine cells. Transgenic mice overexpressing the on-for mPIN formation
cogenic SV40 T antigen (Garabedian et al., 1998; Greenberg etTo determine whether deletion of both alleles at the Pten locus,
al., 1995; Kasper et al., 1998; Masumori et al., 2001) developor loss of heterozygosity (LOH), is required for prostate cancer
both adenocarcinoma and neuroendocrine carcinoma. To de-initiation and progression, we examined cohorts of littermates,
fine the origin of Pten null prostate cancers in the current model,WT (Ptenloxp/loxp;PB-Cre4), heterozygous (Ptenloxp/;PB-Cre4),
and homozygous (Ptenloxp/loxp;PB-Cre4) for Pten prostate-spe- we performed immunohistochemical analyses. Neuroendocrine
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Figure 2. Homozygous Pten deletion leads to adenocarcinoma formation
A: A comparison of pathological phenotype of 4- to 12-week-old PtenL/L;Cre (Mut) mice and their PtenL/L;Cre (WT) littermate controls. Only dorsolateral
lobes are shown here. Epithelial hyperplasia is seen by 4 week of age in the Pten null mice (a compared to b), mPIN is evident by 6 week (c compared
to d; arrows point to cells with aptypia), and this progresses to invasive adenocarcinoma by 9 week of age (compare e and g to f and h).
B: Immunohistochemical analyses indicate that Pten null prostate cancer cells are proliferative, as indicated by Ki67-positive immunostaining (right panels),
and are derived from secretory epithelium (AR, left panels; synaptophysin-negative, middle panels). Middle left panel, high-power image shows synapto-
physin-positive neuroendocrine cells in the mutant prostate (arrow).
cells in normal and neoplastic prostate are devoid of androgen noma, i.e., epithelial origin, differing from T antigen transgenic
mice in which tumors are of neuroendocrine origin.receptor (AR) and are positive for chromogranin A and synapto-
physin (SNP) (for review, see Sciarra et al., 2003). As shown in
Figure 2B, Pten null cancer cells were AR positive (Figure 2B, Homozygous Pten deletion leads to metastatic
prostate cancersleft panels), a hallmark of secretory epithelium, but were negative
for the neuroendocrine cell marker synaptophysin (Figure 2B, Similar to the progression of human prostate cancers, Pten null
prostate cancers also progress from mPIN to invasive adenocar-middle panels). Thus, Pten deletion results in an adenocarci-
cinoma, then to metastatic carcinoma with precisely defined
kinetics. We have observed lymphovascular invasion in the Pten
conditional knockout mice from 12 weeks of age (present in
Table 1. Phenotypes associated with Pten prostate-specific deletion 5 of 11 mice, Table 1; Figures 3Aa, 3Ab, 3Ae, and 3Af) with
subsequent seeding of the subcapsular sinuidal regions ofAge (weeks) WT/Het Homozygous
draining lymph nodes (2 of 11 mice; Figures 3Ac and 3Ag; also4 2/2 normal 4/4 hyperplasia
see supplemental Figure S3) and pulmonary alveolar spaces (36 15/15 normal 9/9 mPIN
9–29 31/31 normal 16/16 invasive carcinoma of 11 mice; Figures 3Ad and 3Ah). The metastatic tumor cells
12–29 5/11 with metastasis in the lung alveolar space remain AR positive (Figure 3B, left
3/14 were died panel) and are negative for PTEN immunostaining (Figure 3B,
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response of Pten null tumors at 3 and 6 days post-castration.
In response to androgen withdrawal, the AR-positive prostatic
epithelium undergoes increased apoptosis, as indicated by dra-
matically increased TUNEL-positive cells, which results in a
reduction of prostate volume following castration (Supplemental
Figures S4 and S5 on Cancer Cell website). In the WT control
prostate, cell death can be easily detected 3 days after castra-
tion and peaks around 6 days (Figure 4A, TUNEL cells in
brown; blue bars on the right panel show quantification). Even
though PTEN is known for its role in negatively regulating apo-
ptosis (Di Cristofano et al., 1998), quantitative analysis indicates
that there is almost 10 times increase of apoptotic cells in the
Pten null prostate 3 days post-castration compared with intact
animal (Figure 4A, red bars; p  0.005), suggesting that the
survival of Pten null prostate cancer cells is androgen depen-
dent. The percentage of apoptotic cell drops when the measure-
ment is taken at 6 days post-castration (Figure 4A, p  0.005),
indicating that Pten null prostate cancer cells may adapt to the
new condition and exhibit enhanced survival, or the androgen-
sensitive population has been gradually depleted.
To test whether mice with Pten null prostate cancer would
benefit from androgen ablation therapy, we castrated Pten con-
ditional knockouts at 2.5–4 months when invasive adenocarci-
noma has already formed. For intact mice, 3/14 Pten prostate
conditional knockouts died by the age of 12–29 weeks (Table
1). In contrast, no lethality is observed in 8/8 castrated Pten null
mice aged from 7–10 months, indicating that Pten null prostate
cancers do benefit from androgen ablation therapy. However,
when these mice were sacrificed 2.5 months after castration,
we found that a substantial number of Pten null prostate cancer
cells remained (Figure 5). Histological analysis demonstrates
that Pten null prostate glands remain 5- to 10-fold larger when
compared to age-matched WT controls (Figure 5, left panels;
comparing LP of WT and mutant). Residual invasive adenocarci-
noma is clearly evident (Figure 5, lower middle panel; red arrows
point to cords of cancerous cells coursing through desmoplastic
stroma). This enlargement, at least in part, is due to the higher
proliferation index in the Pten null prostate. Figure 4B shows
Ki67 staining and quantification (Figure 4B). Surprisingly, the
proliferation indexes of Pten null prostate are 17-fold higher
than age- and genetic background-matched WT controls at 3
days, as well as 6 days and 10 weeks, after castration and are
Figure 3. Homozygous Pten deletion leads to metastatic prostate cancer comparable to the pre-castration stage, suggesting that Pten
deletion leads to androgen-independent or semi-independentA: H&E stained sections show metastatic prostate cancer cells in the lymph-
ovascular system (a and b), subcapsular sinus of a lymph node (c), and cell proliferation. Interestingly, while most of the Pten null pros-
alveolar spaces of the lung (d). A higher magnified picture (boxed region) tate cancer cells remain AR positive, it exhibits a more diffuse,
is shown on the right. heterogeneous immunostaining pattern (Figure 5, right panels).B: Immunohistochemical analyses show that metastatic cells in the pulmo-
The Pten null prostate cancer cells are likely to be sensitive tonary alvelolar spaces are AR positive (left) and PTEN negative (right).
androgen, as indicated by the higher percentage of TUNEL-
positive cells found in Pten null prostate 10 weeks after castra-
tion (Figure 4A). Even though the remaining adenocarcinoma in
right panel). Thus, the conditional Pten null mouse represents Pten conditional knockouts did not lead to premature death
the first animal model in which deletion of an endogenous gene during the short observation period, the knockouts may have
leads to metastatic prostate cancer. the potential, as indicated by their ability to proliferate in the
absence of androgen, to develop into HRPC, similar to that of
Pten null prostate tumors do respond to castration humans, after prolonged castration.
Androgens are critical both for development and function of the
normal prostate gland and for the survival and proliferation of Gene expression analysis revealed similarities between
prostate cancer cells. To assess the response of Pten null pros- molecular mechanisms underlying Pten null murine
tate cancers to hormone ablation therapy, we castrated Pten cancers and human prostate cancers
conditional knockout mice at 16 weeks, when invasive adeno- To provide insights into the molecular events associated with
prostate tumorigenesis, we compared gene-expression profilescarcinoma has already formed, and analyzed the immediate
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Figure 4. Pten null prostate cancers in response to androgen ablation therapy
A: TUNEL assay. 16-week-old Pten conditional knockouts (Mut) and their WT littermates were castrated for indicated period, and prostate tissues were
harvested for TUNEL analysis. Left, TUNEL-positive cells are present in WT and Mut prostates 6 days post-castration; right, quantification. 16-week-old
noncastrated males (intact) were used as controls. p  0.005.
B: Pten null prostate cancer cells remain proliferative in the absence of androgen. Tissue sections from the aforementioned animals were stained with anti-
Ki67 antibody, an indicator of proliferating cells. Left, Ki67-positive cells are present in the prostate glands 10 weeks post-castration; right, quantification.
p  0.005.
of Pten null prostates with age-matched WT controls using in Figures 6B and 6C and summarized in Figure 7, some
changes, such as Nkx3.1 and clusterin (also see Supplementalmicroarray analysis. Our initial studies were focused on animals
26–29 weeks of age since 100% of mutant animals at this stage Figure S1), are directly associated with homozygous Pten dele-
tion and may be regulated by a PTEN-controlled signaling path-have already developed invasive adenocarcinoma. Half of the
prostate was fast frozen for RNA preparation and the other way; other changes are observed during tumor progression,
such as PSCA (Figure 6B), or related to metastasis (osteopontin,half was fixed for pathological evaluation. Histological analysis
indicated that more than 80% of the Pten null prostate tissue Z. Song and P.R.-B., personal communication). These later
groups may represent the additional genetic alterations associ-at this stage was composed by microinvasive cancer cells and
mPIN and less than 20 percent by stoma and inflammatory cells ated with prostate cancer development (Figure 7). Clusterin
(Steinberg et al., 1997) and osterpontin (Hotte et al., 2002) are(data not shown). Statistical analysis of 10290 mouse genes/
ESTs generated a list of 1041 significantly altered genes/ESTs secreted molecules and could be used as potential biomarkers
for cancer staging and molecular diagnostics.(Table S1 in Supplemental Data). Among them, 579 are upregu-
lated in Pten null cancer and 462 are downregulated, and the Recently, molecular signatures of metastatic potential have
been found within the bulk cell mass of primary tumors, sug-top 50 up- and downregulated genes are shown in Figure 6A.
Gene expression changes in the Pten null prostate cancers gesting that metastasis may be an intrinsic property inherited
in the primary cancers (Ramaswamy et al., 2003; van ’t Veerincluded orthologs of genes whose expression also changes in
human prostate cancers, such as upregulated cyclin A, clusterin, et al., 2002). Interestingly, among 17 such “signature genes”
identified in various human cancers, three genes, namelyPSCA, S100P, ERG-1, and osteopontin, as well as down regu-
lated Nkx3.1 and myosin heavy chain 11 (Aaltomaa et al., 1999; Col11, Col12, and Myh11, are also up- or downregulated in
our Pten prostate models (Figure 6A, genes are marked with *),Bowen et al., 2000; Dhanasekaran et al., 2001; Gu et al., 2000;
He et al., 1997; Hotte et al., 2002; Mousses et al., 2002; Rama- consistent with the metastasis potential of Pten prostate cancer
cells described in this study. Taken together, our initial charac-swamy et al., 2003; Reiter et al., 1998; Steinberg et al., 1997).
The corresponding protein expression levels of selected genes, terization of changes in gene expression profiling suggests that
the Pten prostate model will be useful to provide insights intowhich are underlined in Figure 6A, were further confirmed by
immunohistological staining or Western blot analysis. As shown the molecular events associated with prostate cancer progres-
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Figure 5. Invasive adenocarcinoma remains in the Pten null prostate 2.5 months post-castration
Left panels, H&E stained section show enlarged prostate gland in Pten conditional knockout, as compared to its WT littermate after 2.5 months of castration.
Arrows indicate lateral prostate lobes (all images taken at the same magnification). Middle panels, invasive adenocarcinoma in Pten conditional knockout.
Note cords of cancerous cells (red arrows) are mixed with reactive stroma. Right panels, AR-positive staining in WT and mutant prostate tissues 10 weeks
post-castration. Note AR immunostaining is weaker and more heterogeneously diffused post-castration.
sion and metastasis and to elucidate biomarkers and drug tar- Tp53, and Cdkn1B, has yielded little information regarding their
gets for clinical classification and therapeutic intervention. involvement in prostate cancer development. Mice lacking Rb1
are embryonic lethal, and Tp53, Cdkn1B (p27KIP1), or Nkx3.1
Discussion deletion either has no effect on prostate cancer development
(Tp53 and Cdkn1B) (Powell et al., 2003) or results in only a
Animal models for human prostate cancer hyperplasia/dysplasia phenotype in aged animals (Nkx3.1) (Ab-
Animal models that mimic genetic alterations and clinical dulkadir et al., 2002; Bhatia-Gaur et al., 1999; Tanaka et al.,
courses of human prostate cancer are at high demand for the 2000).
study of the molecular mechanisms underlying prostate tumor- As summarized in Figure 7, the Pten prostate cancer model
genesis and for innovation and validation of new anti-cancer mimics the course of human prostate cancer formation: it prog-
strategies. Currently available models for prostate cancer re- resses from hyperplasia to mPIN, then to invasive adenocarci-
search include Huggins’ spontaneous canine model, the Dun- noma, followed by matastasis. Histologically, the Pten null tumor
ning and Noble rat models, the prostate organ reconstitute is derived from secretive epithelium, similar to the origin of the
model, and several transgenic mouse models (Powell et al., majority of human prostate tumors. Notably, the invasive Pten
2003). Mouse models, created via either transgenic or knockout
null prostate cancer cells do respond to androgen ablation,
approaches, are more frequently utilized than the canine or rat
as indicated by increased apoptosis, similar to most humanmodels because of their clearly defined genetics and molecular
prostate cancers. Even though the survival of Pten null prostatetargets. So far, the transgenic adenocarcinoma mouse prostate
cancer cells is androgen sensitive, their proliferation is not af-(TRAMP) is the only mouse prostate cancer model that pro-
fected by androgen withdrawal. The property of androgen-inde-gresses beyond the PIN lesion. However, this SV40 T antigen
pendent growth observed in Pten null prostate cancers maytransgenic model has high neuroendocrine differentiation po-
contribute to hormone-resistant prostate cancer formation. Fi-tential (Garabedian et al., 1998), a phenotype morphologically
nally, Pten homozygous deletion leads to gene expressionand biologically distinct from the adenocarcinomas seen in most
changes seen in human prostate cancers and shares similaritieshuman prostate cancers (Powell et al., 2003). The SV40 T anti-
with other human cancers with metastatic potentials. Thus, Ptengen model also has the limitation that the oncogene is driven
prostate conditional knockout mice described in this study mayby an androgen-dependent promoter and, therefore, it is not
serve as a very useful tool for studying the molecular mecha-an ideal model for studying the mechanism of androgen inde-
nisms underlying prostate cancer metastasis and HRPC for-pendence after androgen ablation. The attempt of genetic inacti-
vation of several classic tumor suppressor genes, such as Rb1, mation.
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Figure 6. Pten deletion leads to dysregulated
gene expressions recapturing molecular
changes seen in human disease
A: A list of top 100 dysregulated genes. RNAs
extracted from four pairs of WT and Mut lit-
termates were used for microarray analysis.
Genes with significantly altered expression were
identified by SAM analysis. Heat map colors re-
flect fold-change values of the ratio in each pair.
Genes whose expression changes are further
confirmed by either Western blot or immunohis-
tochemistry are underlined. Signature genes as-
sociated with human cancer metastasis are
marked with “*.”
B: Western blot analysis. Loss of PTEN leads to
increased AKT phosphorylation, decreased
NKX3.1 protein level, and increased PSCA ex-
pression in Pten null mice.
C: Altered NKX3.1 and Clusterin expressions in
9-week-old Pten null prostate. Upper panels,
double immunofluorescent staining for PTEN (in
red) and Nkx3.1 (in green) indicates that PTEN
and NKX3.1 are colocalized in the nucleus of WT
prostatic epithelium (in yellow). Such localization
is lost in the mutant prostate (right). Note no colo-
calization can be detected in the blood vessels
(white arrows) where NKX3.1 is not expressed.
Middle panels show above sections with DAPI
staining to localize the nucleus. Lower panels,
Immunohistochemical analysis for increased
clusterin expression in the mutant prostate.
Prostate cancer metastasis tumor population. This notion is primarily supported by animal
models in which poorly metastatic cell lines can spawn highlyProstate cancers are known to metastasize; however, so far very
little is known regarding the mechanisms governing prostate metastatic variants after multiple rounds of selection (Clark et al.,
2000; Fidler and Kripke, 1977). Recently, molecular signatures ofcancer metastasis (Cher, 2001; Mundy, 2002). The process of
metastasis is often regarded as a multistep event, and each metastatic potential are found within the bulk of primary tumors
(Ramaswamy et al., 2003; van ’t Veer et al., 2002), suggestingevent must be successful for the entire process to occur. The
successful metastatic cell must leave the primary site, enter that metastasis may be an intrinsic property inherited in the
primary cancers.and survive in the lymphatic and blood circulatory systems,
overcome host defenses, extravasate and grow as a metastatic Interestingly, the expressions of 3 out of 17 such signature
genes were altered in the same directions in our model, indicat-colony (Fidler and Kripke, 2003). Thus it is believed that the
metastatic cell is a rare cell mixed within the heterogenous ing that the Pten conditional knockout mice may provide a
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Figure 7. A summary of the onset and progres-
sion of prostate cancer development in mice
with homozygous Pten deletion in the murine
prostate epithelium and changes in gene ex-
pression
unique tool to study the molecular mechanisms underlying pros- Cancer Cell]). Instead of gradual and cancer stage-dependent
Nkx3.1 downregulation observed in the Myc model, we foundtate cancer metastasis. In fact, among 11 Pten conditional
that Nkx3.1 loss is directly correlated with PTEN loss and AKTknockout mice age 12–29 weeks, 5 had lymphovascular inva-
activation. This correlation can be observed as earlier as 4sion by the prostatic cancer cells. Distance metastases lesions
weeks, a pre-cancer stage (Supplemental Figure S1). Interest-were found in the lymph nodes and lung. Even though autopsy
ingly, some of the genes known to be regulated bysurvey indicates possible metastatic foci in other organs, most
NKX3.1(Magee et al., 2003), such as probasin, are also down-of the metastasis lesions are very small and can be easily missed
regulated in Pten null prostate cancers (Figure 6A). This resultduring histology sectioning. Thus, the actual rate of metastasis
suggests that the mechanisms of Nkx3.1 loss of function incould be higher than what we have identified pathologically.
human prostate cancers may depend on the initial tumorgenicA unique property of prostate cancer is the frequently ob-
events. Indeed, synergistic effect of PTEN and NKX3.1 on tumorserved bone metastasis and subsequent osteoblastic/osteo-
initiation has been reported (Kim et al., 2002).clastic lesions (Bubendorf et al., 2000; Cher, 2001; Harada et
PSCA is another molecule that we identified by microarrayal., 1992; Mundy, 2002). Even though we have not positively
and confirmed to be upregulated in Pten null prostate cancer.identified colonies of prostate cancer cells in bone metastases,
PSCA is expressed in almost all cases of high-grade PIN andwe did observe dramatic bone remodeling activity in 3/11 aged
is overexpressed in 40% of local and as many as 100% of bonePtenloxp/loxp;Cre mice (data not shown). Our analyses also de-
metastatic prostate cancers (Gu et al., 2000). Our array analysistected increased osteopontin expression levels (Supplemental
demonstrated that the expression of PSCA is upregulated by 14-Table S1, and Z. Song, personal communication), an event
fold in Pten null adenocarcinoma, consistent with our previous
known to associate with the presence of bone metastasis in
report that the percentage and intensity of mPSCA-positive cells
men with prostate cancer (Hotte et al., 2002; Thalmann et al.,
increases dramatically in Pten mutant prostates (Dubey et al.,
1999). Further studies using sensitive imaging methodologies 2001). However, further experiments are necessary to distin-
and more prostate-specific markers will help to address this guish whether PSCA serves as a marker for a unique subpopula-
issue. tion of prostate epithelial cells associated with PTEN-controlled
cell transformation or acts as an important player in the process
Changes in gene expression profiling of prostate cancer formation caused by Pten loss.
From the top 100 most significantly regulated genes of our Another robust upregulated gene is clusterin. Clusterin, also
cDNA array analysis, we identified several genes that were well known as testosterone-repressed prostate message-2 (TRPM-2),
documented in the literature for participating prostate cancer dimeric acid glycoprotein, and sulfated glycoprotein-2 (SGP-2),
initiation, progression, and metastasis. is a highly conserved glycoprotein cloned from regressing rat
One of the most interesting genes is Nkx3.1. Nkx3.1 is lo- ventral prostate tissue. Recent studies implicated a protective
cated in human chromosome 8p21, a region frequently deleted function of clusterin against apoptosis in several tissues (July
in human prostate cancer (He et al., 1997), and its inactivation et al., 2002). Clusterin may also be involved in the development
has been shown to correlate with prostate cancer initiation and of androgen independence and resistance to chemotherapy
progression (Bowen et al., 2000). Interestingly, the mechanism (July et al., 2002; Steinberg et al., 1997). The early onset and
of Nkx3.1 loss in Pten null prostate cancers may differ from the persistence of clusterin overexpression indicates clusterin may
contribute to cancer initiation and progression in our model.Myc transgenic model (Ellwood-Yen et al., 2003 [this issue of
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Experimental proceduresPten prostate cancer model and androgen ablation therapy
The seminal works conducted more than 60 years ago by Hug-
Generation of prostate-specific Pten exon 5 deletion
gins (Huggins et al., 1941) have addressed some of the most PtenL/L;C mice
fundamental questions regarding the requirement of androgen To generate PtenL/L;C mice, ARR2Probasin-Cre transgenic line, PB-Cre4
for normal prostate cell as well as prostate cancer cell growth (Wu et al., 2001) on C57BL/6xDBA2 background were crossed to PtenL/L
mice on a 129/Balb/c background. The males offspring with PtenL/;Cand survival (Denmeade and Isaacs, 2002). However, the molec-
genotype were then crossed to PtenL/L females. Only F2 generation of maleular basis underlying the development of androgen-independent
offspring was used in this study.prostate cancer growth after androgen ablation therapy, or
HRPC, has not been resolved to date. Histology and immunochemistry analysis
What is the cellular origin of HRPC? The normal prostatic Tissues are fixed in 10% buffered Formalin for 6–10 hr, followed by gentle
wash and transfer to 70% alcohol. These paraffin-embedded tissues wereepithelium consists of at least three cell types, basal cells, secre-
sectioned (4 m) and stained with hematoxylin & eosin. All IHC staining wastory luminal cells, and neuroendocrine cells (Bui and Reiter,
performed on 4 m sections that were prepared from paraffin-embedded1998; Isaacs, 1999). The secretory luminal cells are terminally
blocks and placed on charged glass slides. Antigen retrieval was performed
differentiated and androgen dependent and will undergo atro- by incubating the slides in 0.01 M citric acid buffer (pH 6.0) at 95C for 30
phy and die upon androgen withdrawal. Neuroendocrine cells min. Slides were then allowed to cool for 20 min in citric acid buffer. After
washing in deionized water, the slides were then transferred to PBS (pHdo not express androgen receptor (AR) and thus are androgen
7.4) (2 	 5 min each). The endogenous peroxidase activity was inactivatedindependent. Basal cells are generally considered to be andro-
in a solution containing 3% hydrogen peroxide (H2O2) in methanol. Thegen independent, although their progeny, the intermediate pre-
following detection and visualization procedures were performed according
cursors, do express low levels of AR and are potentially andro- to manufacturer’s protocol. Slides were counterstained in Mayer’s hematox-
gen responsive. Therefore, HRPC could derive from (1) a ylin, dehydrated, cleared, and coverslipped. Negative control slides were
run without primary antibody. Control slides known to be positive for eachsubpopulation of androgen-independent tumor cells that is
antibody were incorporated.present before hormone ablation therapy (Isaacs, 1999) or (2)
For AR (PG-21, Upstate Biotechnology) and Nkx3.1 (DE#2, a kind giftcells that gained androgen independency due to additional ge-
from Dr. Abate-Shen at the Center for Advanced Biotechnology and Medi-
netic alterations and selected out after castration (Craft et al., cine, Robert Wood Johnson Medical School) staining, pretreated sections
1999). The Pten prostate cancer cells are AR positive and do were first blocked with 10% normal goat serum and then the primary antibod-
ies were diluted as suggested by the manufacturer and incubated overnightrespond to androgen ablation therapy. However, the Pten null
at 4C. Following three washes with PBS, the antigens were visualized usingcells remain proliferative after prolonged castration (Figure 4B).
the biotin-streptavidin based detection system from BioGenex. For clusterin-Thus, Pten deletion either renders prostate cancer cells to prolif-

 (M-18, Santa Cruz Biotechnology) staining, the normal goat serum blocking
erate in the absence of androgen and/or mobilizes androgen- was omitted.
independent basal cells to enter cell cycle. Further studies, such For PTEN (26H9, Cell Signaling Technology) and P-AKT (#9277, Cell
Signaling Technology) staining, pretreated sections were first blocked withas colocalizing Ki-67-positive cells with different prostatic cell-
mouse Ig blocking reagent in the VECTOR M.O.M. Immunodetection Kitspecific markers, will help in distinguishing these possibilities.
(Vector Laboratories) and then incubated with primary antibody at roomOn the molecular level, it has been proposed that restoration
temperature for 30 min.
of AR activity is critical for androgen-refractory prostate cancer For fluorescence double staining, the section was treated as above and
cells, based on clinical findings that HRPC still expresses AR and first stained with mouse antibody (PTEN) followed by signal amplification
androgen-regulated genes, such as prostate-specific antigen with TSA Plus Fluorescence Systems (PerkinElmer). After biotin blocking,
the section was then stained with rabbit antibody (NKX3.1, P-AKT), and(PSA). Several recent studies suggest the presence of crosstalks
signal was amplified with TSA system with different fluorescence.between the PI 3-kinase/Akt and AR signaling pathways. Unfor-
tunately, the effects in different cell lines and from different labs
Apoptosis and proliferation index
often seem contradictory, leading to confusion in the field as Cells undergoing apoptosis were determined by TUNEL assay using the
to whether PI3K/Akt exerts a positive or negative effect on AR. In Situ Cell Death Detection Kit from Roche according to manufacturer’s
instruction. Sections were de-waxed with xylene and rehydrated throughFor example, Manin et al. have claimed that the PI 3-kinase/
graded alcohol. DNA fragmentation was labeled with fluorescein-conjugatedAkt pathway is required for basal and dihydrotestosterone-
dUTP and visualized with converter-POD and DAB. Apoptotic cell was identi-induced AR expression in prostate cell lines (Manin et al., 2002);
fied by positive TUNEL staining and the appearance of apoptotic body. Five
whereas Lin et al. have shown that AKT and Mdm2 form a hundred cells were counted from five different view fields, and the TUNEL-
complex with AR and promote phosphorylation-dependent AR positive cells were presented as numbers per 100 nucleated cells. Cell
proliferation index was determined by Ki67 staining and calculated as aboveubiquitination, resulting in AR degradation by the proteasome
except 100 nucleated cells were counted per view field.(Lin et al., 2002). It is clear from our study that activation of PI3-
kinase/AKT signaling pathway cannot prevent cell death caused
Microarray preparationby androgen ablation. Thus, if there is a crosstalk between AR
Custom cDNA microarrays enhanced for genes expressed in the mouse
and PI3-kinase/AKT pathways in vivo, the effects will not be prostate were prepared on poly-lysine-coated glass microscope slides using
significant in preventing androgen-sensitive cells from apopto- a robotic spotting tool as previously described (Aaltomaa et al., 1999). Each
array consisted of 10290 unique mouse cDNAs, 4511 of which were derivedsis. Consistent with this notion, a recent study suggested that
from cDNA libraries of developing and mature mouse prostate (http://FKHR/AR complex may play an important role in protection of
www.mpedb.org) (Nelson et al., 2002). The remaining 5779 cDNAs wereprostate cancer cells from apoptosis through AKT-independent
chosen from the Research Genetics sequence-verified set of IMAGE clones
pathway (Li et al., 2003). Whether AKT activation will lead to (http://www.resgen.com/products/SVMcDNA.php3) and from the National
androgen-independent cell proliferation, either mediated by AR Institute of Aging 15K set. The clone inserts were amplified by PCR, purified,
and analyzed by gel electrophoresis. All PCR products were sequence-or independent of AR, remains to be investigated.
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Abdulkadir, S.A., Magee, J.A., Peters, T.J., Kallem, Z., Naughton, C.K., Hum-verified prior to spotting. Additional control cDNAs were included, and some
phrey, P.A., and Milbrand, J. (2002). Conditional loss of Nkx3.1 in adult miceclones were spotted twice for a total of 11552 features on the array.
induces prostatic intraepithelial neoplasia. Mol. Cell. Biol. 22, 1495–1503.
Probe construction, microarray hybridization, Backman, S., Stambolic, V., and Mak, T. (2002). PTEN function in mammalian
and data acquisition cell size regulation. Curr. Opin. Neurobiol. 12, 516–522.
The protocol used for indirect labeling of cDNAs was described previously
Bhatia-Gaur, R., Donjacour, A.A., Sciavolino, P.J., Kim, M., Desai, N., Young,(Pritchard et al., 2001). Briefly, cDNA probes that incorporate aminoallyl
P., Norton, C.R., Gridley, T., Cardiff, R.D., Cunha, G.R., Abate-Shen, C., anddUTP (aa-dUTP; Sigma-Aldrich) were made using 30g of total RNA. Purified
Shen, M.M. (1999). Roles for Nkx3.1 in prostate development and cancer.cDNA from Pten null and age-matched wild-type prostates was labeled with
Genes Dev 13, 966–977.either Cy3 or Cy5 monoreactive fluors (Amersham Life Sciences), combined,
and competitively hybridized to microarrays under a coverslip for 16 hr at Bose, S., Crane, A., Hibshoosh, H., Mansukhani, M., Sandweis, L., and
63C. Fluorescent array images were collected for Cy3 and Cy5 emissions Parsons, R. (2002). Reduced expression of PTEN correlates with breast
using a GenePix 4000B fluorescent scanner (Axon Instruments, Foster City, cancer progression. Hum. Pathol. 33, 405–409.
California). Image intensity data were extracted and analyzed using GenePix
Bowen, C., Bubendorf, L., Voeller, H.J., Slack, R., Willi, N., Sauter, G., Gasser,
4.0 microarray analysis software. RNA from four Pten null prostates and four
T.C., Koivisto, P., Lack, E.E., Kononen, J., et al. (2000). Loss of NKX3.1
age-matched wild-type prostates was analyzed using the microarray. Each expression in human prostate cancers correlates with tumor progression.
experiment was performed in duplicate with reversal of the fluorescent label Cancer Res. 60, 6111–6115.
to account for dye effects.
Bubendorf, L., Schopfer, A., Wagner, U., Sauter, G., Moch, H., Willi, N.,
Gasser, T.C., and Mihatsch, M.J. (2000). Metastatic patterns of prostateData normalization and statistical analysis
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intensity-based scatter plot smoother that uses robust locally linear fits to Bui, M., and Reiter, R.E. (1998). Stem cell genes in androgen-independent
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3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA 96, 4240–4245.
upregulated in Pten null prostates and 462 were downregulated. The median
false discovery rate (FDR) was 0.085%, which predicts that 1 of the 1041 Cher, M.L. (2001). Mechanisms governing bone metastasis in prostate can-
cer. Curr. Opin. Urol. 11, 483–488.differentially expressed genes is falsely discovered. The differentially ex-
pressed genes other than ESTs were clustered and visualized with the Cluster
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and TreeView program from Dr. Eisen’s laboratory, and the top 50 most analysis of metastasis reveals an essential role for RhoC. Nature 406, 532–
significant were presented. 535.
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